In a best-case scenario described by a new US Food and Drug Administration report, the agency will conduct half of its planned domestic surveillance inspections this fiscal year, which will end on 30 September.
The 5 May report, “Resiliency Roadmap for FDA Inspectional Oversight,” says the agency still has 3,229 surveillance inspections to carry out in FY 2021 of manufacturers of human and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?